4D Molecular Therapeutics (FDMT) Expected to Announce Earnings on Thursday

4D Molecular Therapeutics (NASDAQ:FDMT) is anticipated to release its quarterly earnings data before the market opens on Thursday, March 6th. Analysts are predicting that the company will report a loss of ($0.80) per share along with revenue amounting to $2.28 million for the quarter.

Price Performance of 4D Molecular Therapeutics

On Thursday, shares of FDMT began trading at $4.80. The company's 50-day moving average stands at $5.28, while the 200-day moving average is significantly higher at $8.74. 4D Molecular Therapeutics has a market capitalization of approximately $221.89 million, a price-to-earnings (PE) ratio of -1.68, and a beta of 2.81, indicating significant volatility. Over the past year, the stock has reached a low of $4.41 and a high of $36.25.

Recent Analyst Ratings

Several brokerage firms have recently updated their ratings and price targets for FDMT. On January 13th, Morgan Stanley lowered its price target for 4D Molecular Therapeutics from $8.00 to $6.00 and categorized the stock as “underweight.” Weiss Ratings also reaffirmed a “sell (d-)” rating on February 19th. In contrast, Leerink Partners raised their stock's rating to “outperform” while reducing the price target from $31.00 to $27.00. Furthermore, BMO Capital Markets downgraded the stock from “outperform” to “market perform,” cutting their price target from $40.00 to $15.00 on the same day. Additionally, Chardan Capital revised their target price from $39.00 to $30.00, maintaining a “buy” recommendation. Overall, one analyst has rated the stock as a sell, two have given it a hold rating, and seven analysts have issued buy ratings. According to data from MarketBeat.com, 4D Molecular Therapeutics holds a consensus rating of “Moderate Buy” with an average price target of $32.13.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc. is a clinical-stage biotherapeutics company that specializes in the development of genetic medicines through its innovative therapeutic vector evolution platform in the Netherlands and the United States. The company is dedicated to advancing a portfolio of genetic medicine products focused on three key therapeutic areas: ophthalmology, cardiology, and pulmonology.

Further Reading

• Five stocks we like better than 4D Molecular Therapeutics
• How to Read Stock Charts for Beginners
• Buffett’s on the Sidelines – Should You Follow?
• What is a Special Dividend?
• AST SpaceMobile Stock Surges 17% After Analyst Upgrade
• What is the Dow Jones Industrial Average (DJIA)?
• 3 Stocks With Triple-Digit PEs That Are Still Worth a Look

Earnings, Stocks, Analysis, Performance